SCHEMBL5066

SCHEMBL5066

[CH2]C1CCc2ccccc2N1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.42
SMYD3 Q9H7B4 1/20 0.41
NPC1 O15118 1/20 0.39
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
PLAU P00749 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
GRIN2B Q13224 1/20 0.34
IDO1 P14902 1/20 0.33
PDPK1 O15530 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23392198 0.88 MAPT (0.43) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL19774297 0.78 MTNR1A (0.47) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL2104951 0.78 MAPT (0.50) NPC1MAPK13MAPK12MAPK11MAPK14
SCHEMBL8771344 0.75 MTNR1A (0.42) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL4130897 0.75 MTNR1A (0.45) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL424121 0.75 MTNR1A (0.45) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL483233 0.75 SMYD3 (0.48) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL2697405 0.75 MTNR1A (0.45) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL13305784 0.75 MTNR1A (0.45) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL6575709 0.75 MTNR1A (0.45) MTNR1ASMYD3NPC1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113683616-A KRAS G12C mutein inhibitors 广州百霆医药科技有限公司 2021-11-23 CN claimed
EP-2155751-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2010-02-24 EP claimed
US-20090221562-A1 NOVEL OPIOID ANTAGONISTS ADOLOR CORPORATION (US) 2009-09-03 US claimed
US-7538110-B2 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction ADOLOR CORPORATION (US) 2009-05-26 US claimed
US-20090099195-A1 Therapeutic Compounds 570 ASTRAZENECA AB (SE) 2009-04-16 US claimed
WO-2008136756-A1 PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2008-11-13 WO claimed
US-7402586-B2 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-07-22 US claimed
EP-1940412-A2 NOVEL OPIOID ANTAGONISTS Adolor Corporation (US) 2008-07-09 EP claimed
US-20070105863-A1 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction MERCK SHARP & DOHME LLC 2007-05-10 US claimed
WO-2007050802-A2 NOVEL OPIOID ANTAGONISTS ADOLOR CORPORATION (US) 2007-05-03 WO claimed
US-20030087921-A1 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-05-08 US claimed
WO-2002098878-A1 TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-12-12 WO claimed
EP-1189901-A1 OXAZAHETEROCYCLES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2002-03-27 EP claimed
US-20020007070-A1 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors LU TIANBAO (US) 2002-01-17 US claimed
US-6326492-B1 ANTICOAGULANT 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-12-04 US claimed
WO-2000073302-A1 OXAZAHETEROCYCLES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-12-07 WO claimed
EP-1036063-A1 HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-09-20 EP claimed
US-6037356-A ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-03-14 US claimed
WO-1999026926-A1 HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-06-03 WO claimed
US-3997348-A FERRIC SALT BLEACHING SOLUTION FUJI PHOTO FILM CO., LTD. (JA) 1976-12-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099195-A1 Therapeutic Compounds 570 OPRL1, OPRK1, OPRM1 MTNR1A 79/4885SMYD3 4282/4885NPC1 851/4885
US-20090221562-A1 NOVEL OPIOID ANTAGONISTS OPRK1, OPRM1, OPRL1 MTNR1A 126/4885SMYD3 2728/4885NPC1 3035/4885
US-20070105863-A1 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction OPRK1, OPRD1, OPRM1 MTNR1A 266/4885SMYD3 4043/4885NPC1 4590/4885
US-20020007070-A1 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors F9, PLG, PLAT MTNR1A 1272/4885SMYD3 4059/4885NPC1 2542/4885
US-20030087921-A1 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors F9, PLG, F2R MTNR1A 1107/4885SMYD3 3935/4885NPC1 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.